Third Harmonic Bio Inc
NASDAQ:THRD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Third Harmonic Bio Inc
Net Income (Common)
Third Harmonic Bio Inc
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
T
|
Third Harmonic Bio Inc
NASDAQ:THRD
|
Net Income (Common)
-$45.5m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hims & Hers Health Inc
NYSE:HIMS
|
Net Income (Common)
$128.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Income (Common)
$8.5B
|
CAGR 3-Years
23%
|
CAGR 5-Years
133%
|
CAGR 10-Years
-7%
|
|
|
Bio-Techne Corp
NASDAQ:TECH
|
Net Income (Common)
$80m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-2%
|
|
|
Repligen Corp
NASDAQ:RGEN
|
Net Income (Common)
$48.9m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
18%
|
|
|
Neurocrine Biosciences Inc
NASDAQ:NBIX
|
Net Income (Common)
$478.6m
|
CAGR 3-Years
46%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
Third Harmonic Bio Inc
Glance View
Third Harmonic Bio Inc is a US-based company operating in industry. The company is headquartered in Cambridge, Massachusetts. The company went IPO on 2022-09-15. Third Harmonic Bio, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on the development of medicine for the treatment of allergic and inflammatory diseases. Its lead product candidate, THB001, is a potent and highly selective, oral small molecule wild-type KIT inhibitor in development for the treatment of mast cell-mediated inflammatory diseases. KIT is a cell surface receptor that acts as the master survival and functional regulator of mast cells. Mast cells are a part of the immune system, and dysfunctional mast cell activity has been implicated in the pathophysiology of a range of allergic and other inflammatory disorders including urticaria, asthma and gastrointestinal disorders, among others. The company has completed Phase Ia clinical trial for THB001, which has demonstrated dose-dependent reductions of serum tryptase, a key biomarker of mast cell activity, which has been shown to correlate with clinical benefit in chronic urticaria patients.
See Also
What is Third Harmonic Bio Inc's Net Income (Common)?
Net Income (Common)
-45.5m
USD
Based on the financial report for Dec 31, 2024, Third Harmonic Bio Inc's Net Income (Common) amounts to -45.5m USD.
What is Third Harmonic Bio Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 3Y
-15%
Over the last year, the Net Income (Common) growth was -48%. The average annual Net Income (Common) growth rates for Third Harmonic Bio Inc have been -15% over the past three years .
